Clinical and Molecular Hepatology

Article	Citations
Preface	597
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	553
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	546
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	370
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver dise	279
Letter to the editor on “Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD”	271
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	203
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	199
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	185
Navigating Discordant Noninvasive Fibrosis Assessments in MASLD: Implications for Generalizability, Clinical Decision-Making, and Resource Allocation	142
Reply to Correspondence: Advancing Immune-Informed and Subgroup-Stratified Research on the MET-TRIB3 Axis	140
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	129
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	128
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”	116
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis	88
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023	84
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	84
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement	83
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation	82
Ethanol‑Specific Stress and RAB25/GCN1 Signaling: Emerging Perspectives in Alcohol‑Associated Liver Disease	82
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	76
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A	73
HCC surveillance after curative treatment: A new frontier for abbreviated MRI: Editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after cura	71
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023	71
Clinical applications of immunogenomics in hepatocellular carcinoma	70

Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates	66
Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma	66
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	63
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	63
Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease	62
Rethinking Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: Unrecognized Risk in Lean Populations	59
Response to Editorial on “MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD”	57
Toward hepatitis C virus elimination using artificial intelligence	57
2025 KASL clinical practice guidelines for management of hepatitis C	56
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target	54
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	54
Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	54
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	54
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease	53
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	52
Liver organoids: Current advances and future applications for hepatology	52
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study	52
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	51
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	51
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate	51
A decade of liver organoids: Advances in disease modeling	49
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	49
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	49
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs	49
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe	48
Reply to correspondence: Sodium-Glucose Cotransporter-2 Inhibitors and Liver Outcomes in Metabolic Dysfunction-associated Steatotic Liver Disease	48
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation	48
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients wi	47
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	44
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	43
Correspondence to letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparis	43
What is new in the 2024 Chinese guidelines for fatty liver disease?	42
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	42
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment	41
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”	41
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”	39
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease	39
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	39
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”	36
Plasma lipidomic and fungal signatures predict early mortality in acute liver failure	35
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study	35
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma	35
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies	34
From Post-Transplant Outcomes to Listing Decisions: Clinical Implications of Comparing Expanded HCC Transplant Criteria	34
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	34
Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy	33
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality	33
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated	33
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver d	33
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	33

Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	32
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C	32
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”	31
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?	31
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”	31
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The	30
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhib	29
Berberine and the gut microbiota - A novel treatment strategy for cholestatic liver disease	29
Precision Chemotherapy in Biliary Tract Cancer moving From Empiric Intensification to Biomarker-Guided Treatment: Editorial on “Molecular determinants of outcome to gemcitabine, cisplatin, and nab-pac	29
Rethinking ACLF Prognosis: Can Machine Learning Outperform Conventional Scores? Editorial on: Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Orga	29
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?	28
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression	28
Immunopathogenesis of liver fibrosis in steatotic liver disease	27
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	27
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogue	27
Discordant FIB-4 and Liver Stiffness in MASLD as related to Histology and Liver-Related Events in a Global Cohort	27
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis	27
Acute-on-chronic liver failure: Terminology, mechanisms and management	27
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences	27
Interaction between sarcopenia and nonalcoholic fatty liver disease	26
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma	26
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	26
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	26
A new Korean nomenclature for steatotic liver disease	26
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma	26
Global incidence and prevalence of nonalcoholic fatty liver disease	26
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohe	26
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load	26
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”	25
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	25
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma	25
Mendelian randomization does not support the effects of G CSF on decompensated liver disease	25
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score?: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and no	24
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation	24
A cost-effectiveness evaluation framework for treatment for metabolic dysfunction-associated steatohepatitis: potential and concerns	24
Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis	24
Gut microbiome and metabolome signatures in liver cirrhosis-related complications	23
Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac in hepatitis B virus-related hepatocellular carcinoma	23
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association	23
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	22
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	22
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	22
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	22
Screening strategy for non-alcoholic fatty liver disease	21
Letter to the editor: Clarifying Residual Drug Effects and Subgroup Outcomes in TDF-to-BSV Switch Trials	21
DNMT1 Facilitates the Progression of MASLD by Impeding Transcription Mediated by HNF4α and PPARα	21
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	21
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	21
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	20
Correspondence: Response to Editorial on “Extending MET–TRIB3 Axis Research in Hepatocellular Carcinoma: Immune Contexture and Patient Subgroups”	20
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	20
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	20
Reply to Correspondence to “Call for Preemptive Treatment of Cytomegalovirus in Patients with Cirrhosis and Acute Decompensation”	20
Regulation of hepatitis B virus cccDNA by metabolic pathways: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”	20
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	20
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis	19
Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches	19
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	19
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	19
Depression and Suicide-Related Events Associated With Tenofovir Use in Chronic Hepatitis B: A Pharmacovigilance Analysis	19
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	18
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	18
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	18
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026	18
JCAD, a new potential therapeutic target in cholestatic liver disease	18
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	18
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	18
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	18
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	17
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	17
vibraA non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: The Baveno VI-SSM combined model: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related e	17
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	17
Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”	17
Harmonized ACLF Prognostication with Explainable Machine Learning Models: Traversing from Counts to Composition	17
Rising burden of alcohol-associated liver disease and cancers: Insights into sex disparities and policy implications: Editorial on “Sex disparities in alcohol-associated liver disease and subtype diff	17
Challenges and Innovations in MASLD and T2DM: Strengthening Personalized Medicine with SGLT2 Inhibitors	17
Extending MET–TRIB3 Axis Research in Hepatocellular Carcinoma: Immune Contexture and Patient Subgroups	16
The magic of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) – Benefits in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2D)	16
Evidence-based hyponatremia management in liver disease	16
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	15

ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling	15
Clinical Implications of Discordant FIB-4 and LSM in MASLD: Integrating Evidence and Optimizing Pathways — A Commentary on the Study by Rabbat et al.	15
Clinical implications of residual changes following HCV clearance: Editorial on “Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy”	15
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues	15
PRMT1-mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression	15
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	15
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by	14
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	14
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	14
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic	14
Plasma Exchange and Abrogation of Monocyte Activation in Wilson’s Disease	13
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization	13
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma	13
Roles of X-box binding protein 1 in liver pathogenesis	13
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatiti	13
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	13
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	13
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	13
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”	13
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and	13
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	13
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	12
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”	12
COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling	12
Non-alcoholic fatty liver disease: Definition and subtypes	12
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”	12
Management of refractory ascites	12
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	12
Clinical Implications of Discordant FIB-4 and LSM in MASLD: Integrating Evidence and Optimizing Pathways: Authors’ reply	11
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	11
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prog	11
A Call for More Efforts to Incorporate Liver in the Metabolic Health Framework	11
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study”	11
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]	11
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma developme	11
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters	11
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults	11
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults	11
Congratulatory remarks	10
Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure	10
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	10
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes melli	10
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer	10
Acute hepatitis C virus infection: clinical update and remaining challenges	10
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	10
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”	10
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic	10
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis	10
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	10
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD	10
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation	9
Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings	9
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features	9
UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL	9
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	9
Burden of Cardiovascular Complications in Steatotic Liver Disease in the United States	9
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma	9
The latest global burden of liver cancer: A past and present threat	9
Letter to the editor on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver dise	9
Hepatorenal syndrome: Current concepts and future perspectives	9
Targeting the innate immune system in treating hepatitis B: prospects for functional cure	9
Letter to the editor 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	9
Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]	9